• BIBP 3226 trifluoroacetate: Benchmarking NPY/NPFF Axis Resea

  2026-04-25

  BIBP 3226 trifluoroacetate empowers researchers to dissect neuropeptide-mediated signaling in anxiety, analgesia, and cardiovascular models with high precision. This guide highlights advanced workflows, data-driven protocol optimizations, and troubleshooting strategies—bridging recent breakthroughs in the adipose-neural axis to practical, reproducible laboratory assays.

• Leupeptin Hemisulfate Salt: Precision in Protease Regulation

  2026-04-24

  Leupeptin hemisulfate salt empowers researchers to achieve rigorous control over protease activity, enabling robust protein degradation studies and high-fidelity viral replication inhibition. This article distills advanced workflow enhancements, troubleshooting strategies, and novel protocol adaptations that maximize the impact of Leupeptin in diverse experimental settings.

• Immunoproteasome-Mediated IL-4Rα Degradation Limits Airway I

  2026-04-24

  This study demonstrates that the immunoproteasome, specifically the LMP7 subunit, degrades IL-4Rα and constrains type 2 airway inflammation and hyperresponsiveness. The findings provide mechanistic insight into how immunoproteasome activity modulates allergic responses, highlighting new intervention points for research in asthma and airway disease.

• Inducing Right Ventricular Cardiomyocytes from Human PSCs: A

  2026-04-23

  Saito et al. present a modified differentiation protocol for human pluripotent stem cells (hPSCs) that enables the specific generation of right ventricular-like cardiomyocytes (RV-like CMs). This study clarifies chamber-specific cardiomyocyte identities, offering new experimental models for investigating right heart diseases and advancing disease modeling and drug discovery.

• Talabostat Mesylate (PT-100): Applied Protocols in Tumor and

  2026-04-23

  Talabostat mesylate (PT-100) is revolutionizing cancer immunology with its dual DPP4 and FAP inhibition, enabling precise modulation of the tumor microenvironment and adaptive immunity. This guide translates current bench research into actionable workflows, comparative insights, and troubleshooting strategies for robust, reproducible results.

• Homer1a Modulates Caspase-6 Signaling in Inflammatory Pain

  2026-04-22

  This preclinical study demonstrates that Homer1a suppresses the caspase-6/TNF-α signaling pathway, attenuating inflammatory pain hypersensitivity in a rat model. The findings clarify a mechanistic link between synaptic scaffolding proteins and caspase-dependent neuroinflammation, highlighting new targets for pain modulation.

• Cyclophosphamide: Applied Protocols in Cancer Research

  2026-04-22

  Cyclophosphamide (SKU A2343) from APExBIO enables reproducible apoptosis induction and immune modulation in both oncology and immunology workflows. This article maps best practices, protocol optimization, and troubleshooting strategies—bridging real-world lab needs and robust quantitative performance.

• Thrombin in Fibrin Matrix Assays: Protocols, Pitfalls, and A

  2026-04-21

  Leverage the unique properties of the Coagulation Factor II (Thrombin) B Chain Fragment [Homo sapiens] from APExBIO to model coagulation and angiogenesis with unparalleled precision. This article distills applied workflows, troubleshooting insights, and research-driven parameters for maximizing reproducibility in fibrin-based and vascular biology assays.

• Autophagy-Liver Metastasis Signature Predicts CRC Prognosis

  2026-04-21

  Bai et al. (2026) present a rigorously validated prognostic signature for colorectal cancer (CRC) based on autophagy and liver metastasis gene expression, using both bulk and single-cell transcriptomic data. Their approach enhances risk prediction and links tumor immune microenvironment alterations to prognosis, offering a new framework for stratifying CRC patients and guiding immunotherapy considerations.

• ATRX-Deficient Glioma Sensitivity to RTK/PDGFR Inhibitors

  2026-04-20

  Pladevall-Morera et al. demonstrate that high-grade glioma cells lacking ATRX are significantly more sensitive to multi-targeted receptor tyrosine kinase (RTK) and PDGFR inhibitors. These findings highlight the importance of ATRX status as a predictive biomarker and provide a rationale for stratifying glioma patients in clinical trials targeting RTK signaling.

• Immunoproteasome-Mediated IL-4Rα Degradation Regulates Type

  2026-04-20

  This study demonstrates that the immunoproteasome, specifically its LMP7 subunit, promotes the degradation of IL-4Rα, thereby restraining type 2 inflammation and airway hyperresponsiveness in asthma models. Pharmacological inhibition or genetic loss of LMP7 increases airway inflammation, underscoring the immunoproteasome's regulatory role and offering insights for future therapeutic targeting.

• WM-8014: A Precision KAT6A Inhibitor for Advanced Senescence

  2026-04-19

  WM-8014 empowers cancer biology researchers to induce p16INK4A–p19ARF-mediated senescence with high selectivity and minimal cytotoxicity. This guide translates recent CRISPR-screening insights and practical workflow refinements for reproducible epigenetic studies using APExBIO's WM-8014.

• Puerarin Modulates Gut Microbiota and Adipose Thermogenesis

  2026-04-18

  This study reveals that puerarin improves glucose and lipid metabolism in type 2 diabetes by restoring gut microbiota balance and enhancing adipose tissue thermogenic capacity. The work employs multi-omics and molecular approaches, providing new mechanistic insights with implications for metabolic disease research.

• Triggered Capture-and-Release Boosts LFA Sensitivity via Amp

  2026-04-17

  This study introduces the AmpliFold 'capture-and-release' strategy to significantly enhance the sensitivity of lateral flow assays (LFAs). By employing cleavable linkers and a dynamic rebinding workflow, the approach addresses kinetic limitations and achieves up to 16-fold signal amplification, offering a tractable improvement for point-of-care diagnostics.

• Prestained Protein Marker (Triple color, EDTA free, 10-250 k

  2026-04-16

  The Prestained Protein Marker (Triple color, EDTA free, 10-250 kDa) addresses the need for accurate, visually distinct molecular weight standards in SDS-PAGE and Western blotting workflows, supporting precise monitoring of protein separation and transfer. It is not intended for applications outside of gel electrophoresis, membrane transfer verification, or where EDTA-free conditions are not required.

465 records 1/31 page Next 12345 下5页 Last page